摘要
肝移植是目前治疗儿童终末期肝病最有效的方法,受者术后需长期服用免疫抑制剂保证移植物功能,但免疫抑制剂的副作用可能会影响术后儿童远期生存。近年来,国内外诸多移植中心开始尝试对移植术后受者的免疫抑制剂进行减量或撤除,部分受者成功停药实现免疫耐受,但目前尚无确切有效的临床方案和免疫监测指标,针对免疫抑制剂撤除的安全性和远期预后的研究十分有限。本文将对儿童肝移植术后免疫抑制剂撤除的临床方案及免疫耐受研究进展进行简要综述,以期为儿童肝移植术后免疫抑制剂撤除和诱导免疫耐受提供一定帮助。
The most effective treatment for end-stage liver disease(ESLD)in children is liver transplantation(LT).After LT,recipients must take immunosuppressants for a long time to maintain graft function.The side effects of immunosuppressants affect long-term recipient survival.Many domestic and global centers have made great efforts to taper or completely remove immunosuppressants in recipients in recent years.Some recipients successfully achieve immune tolerance after withdrawing immunosuppressants.However,there are no definite and effective protocols or indicators for immunization evaluation.And few studies focused upon the safety and long-term outcomes of immunosuppressant withdrawal.This review discussed the protocols and researches of immune tolerance after pediatric LT to provide practical guidance for a withdrawal of immunosuppressants and clinical advice of immune tolerance.
作者
高伟
王若凡
Gao Wei;Wang Ruofan(Department of Pediatric Organ Transplantation,First Central Municipal Hospital,Tianjin Key Laboratory for Organ Transplantation,Tianjin 300192,China;The First Central Clinical School,Tianjin Medical University,Tianjin 300192,China)
出处
《中华器官移植杂志》
CAS
2024年第5期303-307,共5页
Chinese Journal of Organ Transplantation
基金
天津市卫生健康科技项目 (TJWJ2022XK017)。
关键词
肝移植
儿童
免疫抑制剂
免疫耐受
Liver transplantation
Child
Immunosuppressant
Immune tolerance
